Sandbox g30: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
mNo edit summary
Line 7: Line 7:




:* Preferred regimen: 2 months of [[Isoniazid]] 5 (4–6)mg/kg OD {{and}} [[Rifampicin]] 10 (8–12)mg/kg OD {{and}} [[Pyrazinamide]] 25 (20–30)mg/kg OD {{and}} [[Streptomycin]] 15 (12–18)mg/kg OD followed by 7-10 months of [[Isoniazid]] 5 (4–6)mg/kg OD {{and}} [[Rifampicin]] 10 (8–12)mg/kg OD
:* Alternative regimen (1): 2 months of [[Isoniazid]] 5 (4–6)mg/kg OD {{and}} [[Rifampicin]] 10 (8–12)mg/kg OD {{and}} [[Pyrazinamide]] 25 (20–30)mg/kg OD {{and}} [[Streptomycin]] 15 (12–18)mg/kg OD followed by 7-10 months of [[Isoniazid]] 10 (8–12)mg/kg 3 times per week {{and}} [[Rifampicin]] 10 (8–12)mg/kg 3 times per week
:* Alternative regimen (2): 2 months of [[Isoniazid]] 10 (8–12)mg/kg 3 times per week {{and}} [[Rifampicin]] 10 (8–12)mg/kg 3 times per week {{and}} [[Pyrazinamide]] 35 (30–40)mg/kg 3 times per week {{and}} [[Streptomycina]] 15 (12–18)mg/kg 3 times per week followed by 7-10 months of [[Isoniazid]] 10 (8–12)mg/kg 3 times per week {{and}} [[Rifampicin]] 10 (8–12)mg/kg 3 times per week


:* '''Intensive phase treatment'''
:* '''Intensive phase treatment'''

Revision as of 07:03, 8 June 2015


Meningitis, tuberculous ⇧ Return to Top ⇧
  • Tuberculous meningitis[1]


  • Intensive phase treatment
  • Preferred regimen: HRZS
  • Continuation phase
  • Preferred regimen: HR



Note (1): World Health Organization guidelines recommend that ethambutol should be replaced by streptomycin in tuberculous meningitis.[2]
Note (2): A 9– to 12–month course of treatment is recommended for tuberculous meningitis.[3]
Note (3): Adjuvant corticosteroid treatment is recommended unless drug resistance is suspected.[4]
Note (4): Liaise with microbiology laboratory about genotype testing for drug resistance if there is high risk for MDR-TB.
  1. ↑ Blumberg, Henry M.; Burman, William J.; Chaisson, Richard E.; Daley, Charles L.; Etkind, Sue C.; Friedman, Lloyd N.; Fujiwara, Paula; Grzemska, Malgosia; Hopewell, Philip C.; Iseman, Michael D.; Jasmer, Robert M.; Koppaka, Venkatarama; Menzies, Richard I.; O'Brien, Richard J.; Reves, Randall R.; Reichman, Lee B.; Simone, Patricia M.; Starke, Jeffrey R.; Vernon, Andrew A.; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society (2003-02-15). "American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis". American Journal of Respiratory and Critical Care Medicine. 167 (4): 603–662. doi:10.1164/rccm.167.4.603. ISSN 1073-449X. PMID 12588714.
  2. ↑ Treatment of Tuberculosis: Guidelines. WHO Guidelines Approved by the Guidelines Review Committee (4th ed.). Geneva: World Health Organization. 2010. ISBN 9789241547833. PMID 23741786. Retrieved 2015-06-08.
  3. ↑ Treatment of Tuberculosis: Guidelines. WHO Guidelines Approved by the Guidelines Review Committee (4th ed.). Geneva: World Health Organization. 2010. ISBN 9789241547833. PMID 23741786. Retrieved 2015-06-08.
  4. ↑ Thwaites, Guy E.; Nguyen, Duc Bang; Nguyen, Huy Dung; Hoang, Thi Quy; Do, Thi Tuong Oanh; Nguyen, Thi Cam Thoa; Nguyen, Quang Hien; Nguyen, Tri Thuc; Nguyen, Ngoc Hai; Nguyen, Thi Ngoc Lan; Nguyen, Ngoc Lan; Nguyen, Hong Duc; Vu, Ngoc Tuan; Cao, Huu Hiep; Tran, Thi Hong Chau; Pham, Phuong Mai; Nguyen, Thi Dung; Stepniewska, Kasia; White, Nicholas J.; Tran, Tinh Hien; Farrar, Jeremy J. (2004-10-21). "Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults". The New England Journal of Medicine. 351 (17): 1741–1751. doi:10.1056/NEJMoa040573. ISSN 1533-4406. PMID 15496623.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_g30&oldid=1106799"